Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FLAMINCO

Financiado

Therapeutic discovery for Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) – a major cause of colorectal cancer (CRC) and a huge socioeconomic burden in Europe and beyond. IBD comprises diseases that are characterized by chronic inflammation in the gastrointestinal tract... ver más

30/11/2024

INSERM

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-11-30

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

INSERM

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-108996RB-I00 RELEVANCIA FUNCIONAL DE LA FIRMA MOLECULAR EN LAS COMPLICACI... 157K€ Cerrado

PID2021-123918OB-I00 ESTUDIO DE LA HETEROGENIDAD EN LA ENFERMEDAD INFLAMATORIA IN... 339K€ Cerrado

SAF2016-80072-P MODULACION DE LA FIBROSIS INTESTINAL POR EL SISTEMA INMUNE I... 121K€ Cerrado

IJCI-2017-31466 Enfermedad Inflamatoria Intestinal 64K€ Cerrado

SAF2010-18434 FIBROGENESIS Y ENFERMEDAD DE CROHN. ESTUDIO DE MECANISMOS MO... 24K€ Cerrado

CPP2021-009055 Inhibidores No-sistemicos JAK para tratamientos más seguros... 662K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2023-05-25
Fecha Fin: 2024-11-30

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Inflammatory Bowel Disease (IBD) – a major cause of colorectal cancer (CRC) and a huge socioeconomic burden in Europe and beyond. IBD comprises diseases that are characterized by chronic inflammation in the gastrointestinal tract and includes ulcerative colitis (UC) and Crohn’s disease (CD). These diseases are lifelong, causing debilitating symptoms and can be life-threatening. IBD is caused by an interplay between the patient’s genetic predisposition, immune responses and environmental factors. Chronic inflammation with fibrosis is the key driver of disease complications such as stenosis, abscess formation and colon cancer. IBD affects about 3.2 million people in Europe. IBD patients have an increased risk of CRC caused mainly by chronic intestinal inflammation leading to pro-neoplastic effects. In fact, IBD patients have an alarming 2- to 5- fold increased risk of developing CRC compared to the general population. Despite many treatment options, there is no cure for IBD. The IBD health economic burden in Europe is high and estimated at over 5B €/year. It is widely accepted that to overcome the challenges and to break through the therapeutic ceiling combination therapies or completely novel approaches will be needed. Due to the increasing incidence and prevalence and associated burden of IBD, the lack of effective long-term treatment options and the associated risks including CRC; IBD remains an important unmet medical need with an urgent need for novel therapies that can improve patient outcome. Here we will explore the use of a completely novel class of molecules exploiting a unique first-in-class mechanism-of-action and validate their efficacy as a therapeutic for IBD. Proof-of-concept studies will be performed in state-of-the-art mouse models. The data obtained will represent a robust data package towards IND for this indication. We propose a novel therapeutic option for IBD that has the potential to address this important unmet medical need.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores